INSM Price Prediction Next Week
Analysis and Insights
News and Event Impact:
Insmed (INSM) has received positive news from UBS, which raised its price target from $105 to $110 while maintaining a Buy rating. This adjustment is based on anticipation of positive Phase 2 data for TPIP in Pulmonary Arterial Hypertension by mid-2025, with potential pulmonary vascular resistance reductions of 27%-32%. Additionally, RBC Capital Markets initiated coverage with an Outperform rating and a $100 price target, highlighting Brensocatib's $6.5 billion opportunity and strong launch potential.
Technical Indicators:
Current technical indicators for INSM show:
- RSI (6, 12, 14): 32.42, 40.72, 42.43 (oversold, indicating potential rebound)
- MACD: -0.15 (slightly bearish but nearing zero)
- Stochastic Oscillator: 15.64 (oversold)
- Fibonacci Levels: Pivot at 78.16, with resistance at 82.22 and 84.72, and support at 74.10 and 71.60.
Price Prediction and Recommendation:
Given the positive news sentiment, strong analyst ratings, and oversold technical indicators, INSM is expected to rebound. The stock is predicted to reach $82 next week, targeting the first Fibonacci resistance level.
Recommendation: Buy INSM at the current price of $74.51, with a target price of $82.
INSM Similar Chart Price Prediction
The price of INSM is predicted to go up -2.94%, based on the high correlation periods with STM. The similarity of these two price pattern on the periods is 91.33%.
INSM
STM
Down: -2.94%Similarity: 91.33%
INSM Revenue Forecast
INSM EPS Forecast
INSM FAQs
What is INSM revenue forecast for next quarter？
INSM Analyst's Forecast
Stephen Willey
Stifel
Strong Buy
2025-02-21
Price Target
$97 → $96
Upside
+18.43%
Stifel lowered the firm's price target on Insmed to $96 from $97 and keeps a Buy rating on the shares. With mid-year Phase 2 PAH data for TPIP and year-end Phase 2b CRSsNP data for brensocatib, the firm continues to view FY25 as "a critical year for the company," the analyst tells investors in a post-earnings note.
Stephen Willey
Stifel
Strong Buy
2025-02-11
Price Target
$88 → $97
Upside
+21.42%
Jessica Fye
JP Morgan
Buy
2024-11-22
Price Target
$74 → $83
Upside
+13.47%
